QIAGEN Celebrates 4,000th QIAcube Connect Placement, Reinforcing Commitment to Automated Sample Processing In a major development within the life sciences and diagnostics sectors, QIAGEN N.V., headquartered in Venlo, Netherlands, and Germantown, Maryland, has achieved a significant milestone with the placement of its 4,000th QIAcube Connect instrument. This notable accomplishment underscores the company’s leading position in the automation of sample processing, a critical component in laboratories worldwide.The QIAcube Connect, known for its reliability and efficiency, is a vital tool for laboratories striving to streamline workflows and enhance productivity. The instrument has gained widespread adoption, ...
In a significant stride towards bolstering its oncology diagnostics capabilities, QIAGEN (NYSE: QGEN Frankfurt Prime Standard: QIA) has recently announced the expansion of its portfolio focused on detecting minimal residual disease (MRD) in oncology through two strategic partnerships. These collaborations are set to accelerate the utilization of MRD testing in clinical studies, facilitating joint developmental projects with pharmaceutical companies in the realm of companion diagnostics. This move indicates QIAGEN s commitment to positioning itself at the forefront of innovative cancer diagnostics, thereby enhancing patient care and treatment precision.MRD, referring to the small number of cancer cells that m...
In a bold move set to reshape the future of laboratory operations, QIAGEN, a leading global provider of sample and assay technologies, has announced its ambitious plans to launch three new sample preparation instruments between 2025 and 2026. This initiative aims not only to enhance automation in laboratories but also to address vital demands for efficiency and sustainability across varying scientific sectors.Venlo, Netherlands-based QIAGEN, known for its commitment to innovation, is taking significant strides to expand and strengthen its portfolio in automated sample preparation. The company’s flagship product, the QIAsymphony Connect, exemplifies this commitment as it represents the next generation of it...
In a significant advancement for malaria research and public health, QIAGEN N.V. headquartered in Venlo, Netherlands, has announced the launch of its innovative QIAprep Plasmodium Kit. This novel solution, accompanied by two complementary assays, is set to enhance malaria research and surveillance efforts globally, addressing one of the most challenging public health issues of our time.The QIAprep Plasmodium Kit streamlines the process of detecting malaria-causing parasites by integrating sample preparation and quantitative PCR (qPCR) into a seamless, efficient workflow. By allowing rapid and accessible detection of the Plasmodium species from blood samples, this state-of-the-art kit empowers researchers and...
In a strategic move to bolster its standing in the infectious diseases and precision medicine sectors, QIAGEN N.V. has announced plans to relocate its QIAstat-Dx operations to a newly established facility in Esplugues de Llobregat, near Barcelona. This initiative, part of a long-term investment strategy, aims to enhance the company s capabilities in syndromic testing an essential tool for accurately diagnosing the underlying causes of illnesses.As public health concerns surrounding infectious diseases escalate globally, the demand for rapid and reliable testing methodologies becomes paramount. The QIAstat-Dx system stands at the forefront of this endeavor, offering clinicians the ability to conduct multiplex...
QIAGEN: A Strong Q3 2024 Performance Defies Market Trends In an era characterized by fluctuating market conditions and shifting consumer demands, QIAGEN N.V. has demonstrated remarkable resilience and adaptability. The company reported solid growth in the third quarter of 2024, exceeding analysts expectations while navigating challenges posed by a competitive landscape and global economic uncertainties. This article dissects QIAGEN s financial performance in Q3 2024, analyzes key growth drivers, and contrasts its current successes against previous downturns, particularly the dramatic revenue decrease reported by the company’s corporate clients. Financial Highlights of Q3 2024 Unprecedented Sales GrowthQI...
QIAGEN has officially launched its groundbreaking QIAcuityDx digital PCR system, marking a significant advancement in clinical testing for oncology. This innovative platform broadens the range of applications for the highly successful QIAcuity digital PCR technology and is now set to impact clinical laboratories across North America and the European Union.The QIAcuityDx system is designed to provide absolute quantitation, a crucial capability for the precise monitoring of low-abundance targets in clinical diagnostics. This level of accuracy is essential for detecting minimal residual disease, characterizing tumor mutations, and tracking patient responses to treatment, thereby enhancing personalized medicine ...
In an era where technological advancements are reshaping the landscape of forensic science, the recent partnership between QIAGEN and Bode Technology marks a significant milestone in the realm of forensic genetic genealogy. QIAGEN, a global leader in diagnostic and genomic solutions, has chosen Bode Technology as its exclusive commercial partner to facilitate the accelerated utilization of the GEDmatch PRO genealogy database. This powerful collaboration aims to enhance law enforcement efforts and improve the identification of human remains, thereby addressing pressing needs within the forensic community.The GEDmatch PRO database, renowned for its utility in forensic investigations, provides a platform for la...
QIAGEN Revolutionizes Tuberculosis Testing in Children with QuantiFERON-TB Gold Plus, Welcomed by New U.S. GuidelinesQIAGEN, a leading provider of innovative molecular diagnostics solutions, has received a significant boost with the American Academy of Pediatrics (AAP) recommending the use of IGRA tests, such as QuantiFERON-TB Gold Plus, for screening children of all ages who are at risk of tuberculosis (TB) infection. This new recommendation aligns with the growing trend in U.S. tuberculosis control guidelines, emphasizing the use of modern blood-based tests to effectively combat the spread of this potentially deadly bacterial infection.The AAP s endorsement of IGRA tests is a significant milestone, recogni...
In an era driven by innovation and sustainable practices, the biotechnology and sustainable resources sectors have witnessed significant breakthroughs. This article explores two pivotal advancements: Kraig Biocraft Laboratories successful completion of its first commercial production run of BAM-1 spider silk hybrids and the joint venture between CoTec Holdings Corp. and Mkango Resources Ltd. to roll out rare earth magnet recycling technology in the United States. Kraig Biocraft Laboratories Spider Silk SuccessKraig Biocraft Laboratories (OTCQB: KBLB) has announced the successful cocoon production for the first commercial run of its BAM-1 spider silk hybrids. This achievement marks a significant milestone f...
Sources:
Qiagen N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Qiagen N v’s corporate clients.
For your research, we’ve provided 9 tables on Qiagen N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
92.23 %